162 related articles for article (PubMed ID: 33410680)
1. Synthesis and Biological Evaluation of (2
Kaneko M; Li Z; Burk M; Colis L; Herzon SB
J Am Chem Soc; 2021 Jan; 143(2):1126-1132. PubMed ID: 33410680
[TBL] [Abstract][Full Text] [Related]
2. The Mechanism of Action of (-)-Lomaiviticin A.
Herzon SB
Acc Chem Res; 2017 Oct; 50(10):2577-2588. PubMed ID: 28956437
[TBL] [Abstract][Full Text] [Related]
3. Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
Colis LC; Herzon SB
Bioorg Med Chem Lett; 2016 Jul; 26(13):3122-3126. PubMed ID: 27177826
[TBL] [Abstract][Full Text] [Related]
4. Synthesis studies on the lomaiviticin A aglycone core: development of a divergent, two-directional strategy.
Feldman KS; Selfridge BR
J Org Chem; 2013 May; 78(9):4499-511. PubMed ID: 23581811
[TBL] [Abstract][Full Text] [Related]
5. Development of enantioselective synthetic routes to (-)-kinamycin F and (-)-lomaiviticin aglycon.
Woo CM; Gholap SL; Lu L; Kaneko M; Li Z; Ravikumar PC; Herzon SB
J Am Chem Soc; 2012 Oct; 134(41):17262-73. PubMed ID: 23030272
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective synthesis of the lomaiviticin aglycon full carbon skeleton reveals remarkable remote substituent effects during the dimerization event.
Lee HG; Ahn JY; Lee AS; Shair MD
Chemistry; 2010 Nov; 16(44):13058-62. PubMed ID: 20976820
[No Abstract] [Full Text] [Related]
7. Synthesis of the bis(cyclohexenone) core of (-)-lomaiviticin A.
Rose JA; Mahapatra S; Li X; Wang C; Chen L; Swick SM; Herzon SB
Chem Sci; 2020 Jul; 11(28):7462-7467. PubMed ID: 34123029
[TBL] [Abstract][Full Text] [Related]
8. The cytotoxicity of (-)-lomaiviticin A arises from induction of double-strand breaks in DNA.
Colis LC; Woo CM; Hegan DC; Li Z; Glazer PM; Herzon SB
Nat Chem; 2014 Jun; 6(6):504-10. PubMed ID: 24848236
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and first biological evaluation of 1-aza-9-oxafluorenes as novel lead structures for the development of small-sized cytostatics.
Brachwitz K; Hilgeroth A
Bioorg Med Chem Lett; 2002 Feb; 12(3):411-3. PubMed ID: 11814809
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for DNA cleavage by the potent antiproliferative agent (-)-lomaiviticin A.
Woo CM; Li Z; Paulson EK; Herzon SB
Proc Natl Acad Sci U S A; 2016 Mar; 113(11):2851-6. PubMed ID: 26929332
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of the fully glycosylated cyclohexenone core of lomaiviticin A.
Gholap SL; Woo CM; Ravikumar PC; Herzon SB
Org Lett; 2009 Oct; 11(19):4322-5. PubMed ID: 19719089
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of neopeltolide and analogs.
Cui Y; Balachandran R; Day BW; Floreancig PE
J Org Chem; 2012 Mar; 77(5):2225-35. PubMed ID: 22329423
[TBL] [Abstract][Full Text] [Related]
13. Mimicking the biological activity of diazobenzo[b]fluorene natural products with electronically tuned diazofluorene analogs.
Zeng W; Eric Ballard T; Tkachenko AG; Burns VA; Feldheim DL; Melander C
Bioorg Med Chem Lett; 2006 Oct; 16(19):5148-51. PubMed ID: 16870443
[TBL] [Abstract][Full Text] [Related]
14. Polycyclic aromatic compounds as anticancer agents: synthesis and biological evaluation of dibenzofluorene derivatives.
Becker FF; Mukhopadhyay C; Hackfeld L; Banik I; Banik BK
Bioorg Med Chem; 2000 Dec; 8(12):2693-9. PubMed ID: 11131160
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of the C4-epi-lomaiviticin B core reveals subtle stereoelectronic effects.
Lee AS; Shair MD
Org Lett; 2013 May; 15(10):2390-3. PubMed ID: 23659351
[TBL] [Abstract][Full Text] [
